Hemab Therapeutics(NASDAQ) COAG

Hemab Therapeutics Holdings, Inc. treats rare blood diseases. These medicines help blood clot to prevent dangerous bleeding. The firm helps patients who have few other options.

Clotting Solutions for Rare Diseases

• Sutacimig (HMB-001): Antibody therapy that helps blood clot by targeting two different proteins; currently being tested in human trials for rare bleeding disorders.
• HMB-002: Preventive treatment for Von Willebrand Disease given as a shot under the skin; works to increase important clotting factors in the body.
• HMB-003: Early-stage medicine designed to stop blood clots from breaking down too quickly; currently in preclinical development for conditions like heavy menstrual bleeding.
• Discovery Programs: Research efforts identifying new ways to treat abnormal bleeding using a specialized peptide discovery platform.

Strategic Partnerships and Milestones

• Completed a corporate reorganization on March 30, 2026, to become a Delaware-based holding company.
• Raised $317.2 million in net proceeds through an initial public offering on May 4, 2026.
• Licensed the DuoBody technology platform from Genmab in April 2020 to develop specialized antibodies for bleeding conditions.
• Entered a license agreement with Novo Nordisk in November 2019 for rights to specific antibody targets.
• Partnered with Gubra in November 2023 to use its discovery platform for identifying new drug candidates.

A Specialized Focus on Innovation

Hemab focuses on using complex biotechnology to solve very specific problems in how human blood clots. The company maintains research and clinical operations in both the United States and Denmark to manage its global development.

Tracking the Recent Financials

• Net loss was $46.8 million for the six-month period ended June 30, 2026.
• Research and development expenses were $39.8 million for the six-month period ended June 30, 2026.
• Cash, cash equivalents, and marketable securities totaled $457.5 million as of June 30, 2026.
• Accumulated deficit reached $228.7 million as of June 30, 2026.
• Market capitalization was $1.5 billion in the first quarter of 2026.

The Bottom Line

Hemab has evolved from a research startup into a clinical-stage biotechnology firm with several medicines in human testing. Its strategy relies on licensing advanced technology to treat rare diseases with significant unmet needs.